Evidence map›Paper›PMID 17904185›Full record

ArticleVirology2008

Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.

M E Fluet, A C Whitmore, D A Moshkoff, K Fu, Y Tang, M L Collier, A West, D T Moore, R Swanstrom, R E Johnston and 1 more

Open access · greenAbstract read
In one paragraph

Article in Virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

M E FluetCarolina Vaccine Institute, University of North Carolina, Chapel Hill, NC 27599, USA. meagan_fluet@med.unc.edu
A C Whitmore
D A Moshkoff
K Fu
Y Tang
M L Collier
A West
D T Moore
R Swanstrom
R E Johnston
N L Davis
University of North Carolina at Chapel Hill · US

Funding

PROTEIN STRUCTURE IN IMMUNOGENICITYP01AI046023 · NIAID · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI JOHNSTON, ROBERT E. · 1999 to 2004
$10.9M
VRP IMMUNOGENICITY FOR A SECOND GENERATION VACCINEP01AI050246 · NIAID · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI JOHNSTON, ROBERT E. · 2001 to 2005
$6.2M
NIAID NIH HHS P01 AI046023NIAID NIH HHS P01 AI050246NIAID NIH HHS P01 AI46023
6 · The paper itself

Abstract

Genetic vaccines are engineered to produce immunogens de novo in the cells of the host for stimulation of a protective immune response. In some of these systems, antigens engineered for rapid degradation have produced an enhanced cellular immune response by more efficient entry into pathways for processing and presentation of MHC class I peptides. VEE replicon particles (VRP), single cycle vaccine vectors derived from Venezuelan equine encephalitis virus (VEE), are examined here for the effect of an increased rate of immunogen degradation on VRP vaccine efficacy. VRP expressing the matrix capsid (MA/CA) portion of SIV Gag were altered to promote rapid degradation of MA/CA by various linkages to co-translated ubiquitin or by destabilizing mutations and were used to immunize BALB/c mice for quantitation of anti-MA/CA cellular and humoral immune responses. Rapid degradation by the N-end rule correlated with a dampened immune response relative to unmodified MA/CA when the VRP carried a glycoprotein spike from an attenuated strain of VEE. In contrast, statistically equivalent numbers of IFNgamma(+)T-cells resulted when VRP expressing unstable MA/CA were packaged with the wild-type VEE glycoproteins. These results suggest that the cell types targeted in vivo by VRP carrying mutant or wild type glycoprotein spikes are functionally different, and are consistent with previous findings suggesting that wild-type VEE glycoproteins preferentially target professional antigen presenting cells that use peptides generated from the degraded antigen for direct presentation on MHC.

Indexed as

AnimalsAntibodies, ViralAntibody SpecificityAntigens, ViralCapsid ProteinsCell LineCricetinaeEncephalitis Virus, Venezuelan EquineGene Products, gagGenetic VectorsGlycoproteinsImmunizationInterferon-gammaMiceMice, Inbred BALB CRepliconAntibodies, ViralAntigens, ViralCapsid ProteinsGene Products, gagGlycoproteinsInterferon-gammaUbiquitinViral Matrix ProteinsViral Vaccines

Identifiers

PMID17904185
PMCPMC2288739
OpenAlexW1970939429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.